Appln. No. 10/565,238

Amdt. dated February 9, 2009

Reply to Office action of October 8, 2008

## Amendments to the Specification:

On page 14, please replace the second paragraph with the amended paragraph:

Treatment with IB-MECA  $(N^6-(3-iodobenzy1)-adenosine-5'-N-methyluronamide)$  (10 µg/kg) was initiated on day 14 after vaccination and was orally administered by gavage, twice daily. Another group was treated with Methotrexate (MTX) (1.5 mg/kg) intraperitoneally every 3 days, starting on day 14th after vaccination. The control group in each experiment received vehicle only (DMSO in a dilution corresponding to that of the drugs).